AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

Delisting risk

ADXN · NASDAQ · Biotechnology

Addex Therapeutics (ADR) (ADXN)

Develops allosteric CNS drug candidates through internal programs, partnerships, and investments.

$3.61

Pre-market+0.06 (+1.69%)

At close$3.55(−2.74%)

Watchlist

Something off on this page? Send us feedback.

Breakdown13F · 13D/G · Form 4

	Insiders7 holders · as of Mar 25, 2026	60.22%	741.8K ADS
	Otherremainder	39.78%	490.1K ADS

1.23M ADS (1 ADS = 30 ordinary shares) as of Aug 22, 2026 · holders as of their latest filing

The share count is from the company's Dec 2022 annual report; nothing newer is on file here.

The reported float (578.7K, 80.3% free) does not reconcile with the share count, so it is not shown.

Top shareholders13F · 13D/G · Form 4

Holder	Stake	Shares	Evidence
Timothy Mark DyerInsiderdirector, 10 percent owner, officer: Chief Executive Officer	45.59%	16.85M ordinary	Form 4filed Mar 18, 2026 ↗
Vincent Michael LawtonInsiderdirector	6.79%	2.51M ordinary	Form 4filed Mar 25, 2026 ↗
Raymond George HillInsiderdirector	3.69%	1.37M ordinary	Form 4filed Mar 25, 2026 ↗
Roger MillsInsiderdirector, officer: CHIEF MEDICAL OFFICER	2.13%	785,976 ordinary	Form 4filed Mar 25, 2026 ↗
Mikhail KalinichevInsiderofficer: HEAD OF TRANSLATIONAL SCIENCE	0.83%	306,765 ordinary	Form 4filed Mar 25, 2026 ↗
Isaac MankeInsiderdirector	0.59%	219,561 ordinary	Form 4filed Mar 18, 2026 ↗
Jason Raleigh NunnInsiderdirector	0.59%	219,561 ordinary	Form 4filed Mar 18, 2026 ↗
Credit Suisse AG/000000000Strategic	—4.95% of class, as filed	—	13D/Gfiled Feb 14, 2022 ↗
Caxton CorporationStrategic	—6.00% of class, as filed	—	13G/Afiled Feb 14, 2022 ↗
Enterprise Associates 15, L.P.Institution	—21.50% of class, as filed	—	13D/Gfiled Jan 22, 2021 ↗
Goldman Sachs & Co. LLCStrategic	—6.10% of class, as filed	—	13D/Gfiled Feb 14, 2022 ↗
New Leaf BPO Associates I, L.P.Institution	—4.50% of class, as filed	—	13G/Afiled Feb 11, 2022 ↗
New Leaf Biopharma Opportunities I, L.P.Insider	—6.20% of class, as filed	—	13G/Afiled Feb 18, 2022 ↗
Page 2 of 10 PagesInsider	—7.10% of class, as filed	—	13Gfiled Feb 10, 2021 ↗
Steven BoydInsider	—9.99% of class, as filed	—	13Gfiled Feb 15, 2022 ↗

13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report

Institutions13F

No 13F holders on record.

Ownership statements13D/G · 5% or more, as filed

Holder	% of class	Shares	Form	Filed
Timothy Mark Dyer	8.98%		13D	Aug 27, 2026 ↗

Addex Therapeutics (ADR) (ADXN)

Breakdown13F · 13D/G · Form 4

Top shareholders13F · 13D/G · Form 4

Institutions13F

Ownership statements13D/G · 5% or more, as filed

Insider tradesForm 4

Latest trades

CongressHouse and Senate disclosures